Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 50
2024 49
2025 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Management of pediatric hemolytic uremic syndrome.
Gülhan B, Özaltın F, Fidan K, Özçakar ZB, Söylemezoğlu O. Gülhan B, et al. Turk J Pediatr. 2024;66(1):1-16. doi: 10.24953/turkjped.2023.596. Turk J Pediatr. 2024. PMID: 38523374 Free article. Review.
Several situations, including infections, medications, malignancies, and transplantation can trigger endothelial damage. On the HUS spectrum, atypical hemolytic uremic syndrome (aHUS) deserves special attention in pediatric patients, as it can cause en …
Several situations, including infections, medications, malignancies, and transplantation can trigger endothelial damage. On the HUS spectrum …
Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy.
Java A. Java A. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):200-205. doi: 10.1182/hematology.2024000543. Hematology Am Soc Hematol Educ Program. 2024. PMID: 39644051 Free PMC article. Review.
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy typically characterized by anemia, thrombocytopenia, and end-organ injury. aHUS occurs due to endothelial injury resulting from overactivation of the alternative pathway of the c …
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy typically characterized by anemia, thr …
Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study.
Brocklebank V, Walsh PR, Smith-Jackson K, Hallam TM, Marchbank KJ, Wilson V, Bigirumurame T, Dutt T, Montgomery EK, Malina M, Wong EKS, Johnson S, Sheerin NS, Kavanagh D. Brocklebank V, et al. Blood. 2023 Oct 19;142(16):1371-1386. doi: 10.1182/blood.2022018833. Blood. 2023. PMID: 37369098 Free PMC article.
Historically, the majority of patients with complement-mediated atypical hemolytic uremic syndrome (CaHUS) progress to end-stage kidney disease (ESKD). ...
Historically, the majority of patients with complement-mediated atypical hemolytic uremic syndrome (CaHUS) progr …
Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial.
Garnier A, Brochard K, Kwon T, Sellier-Leclerc AL, Lahoche A, Launay EA, Nobili F, Caillez M, Taque S, Harambat J, Michel-Bourdat G, Guigonis V, Fila M, Cloarec S, Djamal-Dine D, de Parscaux L, Allard L, Salomon R, Ulinski T, Frémeaux-Bacchi V, Morin C, Olivier-Abbal P, Colineaux H, Auriol F, Arnaud C, Kieffer I, Brusq C. Garnier A, et al. J Am Soc Nephrol. 2023 Sep 1;34(9):1561-1573. doi: 10.1681/ASN.0000000000000182. Epub 2023 Jun 12. J Am Soc Nephrol. 2023. PMID: 37303085 Free PMC article. Clinical Trial.
The use of eculizumab, a monoclonal antibody inhibiting terminal complement complex, has demonstrated remarkable success in atypical hemolytic uremic syndrome, but its use in uncontrolled studies to treat STEC-HUS has yielded inconsistent results. ...
The use of eculizumab, a monoclonal antibody inhibiting terminal complement complex, has demonstrated remarkable success in atypical …
An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group.
Nester CM, Feldman DL, Burwick R, Cataland S, Chaturvedi S, Cook HT, Cuker A, Dixon BP, Fakhouri F, Hingorani SR, Java A, van de Kar NCAJ, Kavanagh D, Leung N, Licht C, Noris M, O'Shaughnessy MM, Parikh SV, Peyandi F, Remuzzi G, Smith RJH, Sperati CJ, Waldman M, Walker P, Vivarelli M. Nester CM, et al. Kidney Int. 2024 Sep;106(3):326-336. doi: 10.1016/j.kint.2024.05.021. Kidney Int. 2024. PMID: 39174192 Free article.
Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is not Shiga toxin-associated hemolytic uremic syndrome. ...A Delphi approach was used to define and interrogate some of the key issues related …
Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is …
Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.
Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, Gasteyger C, Java A, Leguizamo J, Lloyd-Price L, Pham TP, Symonds T, Tomazos I, Wang Y. Mauch TJ, et al. J Comp Eff Res. 2023 Sep;12(9):e230036. doi: 10.57264/cer-2023-0036. Epub 2023 Jul 29. J Comp Eff Res. 2023. PMID: 37515502 Free PMC article.
Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. ...
Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic …
Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition.
Ardissino G, Cresseri D, Mancuso MC, Capone V, Porcaro L, Amico V, Tangredi M, Grovetti E, Griffini S, Castellano G, Montini G, Consonni D, Cugno M; HUS-ItalKid Network.. Ardissino G, et al. J Nephrol. 2024 May;37(4):1017-1026. doi: 10.1007/s40620-023-01873-9. Epub 2024 Jan 27. J Nephrol. 2024. PMID: 38280096
BACKGROUND: Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD). ...
BACKGROUND: Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontro …
Adolescence-onset atypical hemolytic uremic syndrome: is it different from infant-onset?
Celegen K, Gulhan B, Fidan K, Yuksel S, Yilmaz N, Yılmaz AC, Demircioğlu Kılıç B, Gokce I, Kavaz Tufan A, Kalyoncu M, Nalcacıoglu H, Ozlu SG, Kurt Sukur ED, Canpolat N, K Bayazit A, Çomak E, Tabel Y, Tulpar S, Celakil M, Bek K, Zeybek C, Duzova A, Özçakar ZB, Topaloglu R, Soylemezoglu O, Ozaltin F. Celegen K, et al. Clin Exp Nephrol. 2024 Oct;28(10):1027-1037. doi: 10.1007/s10157-024-02505-7. Epub 2024 May 5. Clin Exp Nephrol. 2024. PMID: 38704765
BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare, mostly complement-mediated thrombotic microangiopathy. ...
BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare, mostly complement-mediated thrombotic microangi …
Molecular pharmacology in complement-mediated hemolytic disorders.
Bortolotti M, Barcellini W, Fattizzo B. Bortolotti M, et al. Eur J Haematol. 2023 Sep;111(3):326-336. doi: 10.1111/ejh.14026. Epub 2023 Jun 12. Eur J Haematol. 2023. PMID: 37308291 Review.
In the last decade, a deeper understanding of the pathogenesis of complement mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease (CAD), warm type autoimmune hemolytic anemia (AIHA) with complement activation (wAIHA), and aty …
In the last decade, a deeper understanding of the pathogenesis of complement mediated hemolytic disorders, such as paroxysmal nocturnal hemo …
100 results